繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 综合药讯 >> LIPOSYN III(静脉注射脂肪乳剂)

LIPOSYN III(静脉注射脂肪乳剂)

2011-02-28 17:19:34  作者:新特药房  来源:中国新特药网天津分站  浏览次数:269  文字大小:【】【】【
简介: Information on Liposyn III WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impai ...

Information on Liposyn III

WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.
Research indicates that patients with impaired kidney function, including premature neonates, whoreceive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.


INDICATIONS AND USAGE
Liposyn III (intravenous fat emulsion) is indicated as a source of calories for patients requiring parenteral nutrition. Where such nutrition is required for extended periods of time (more than 5 days), Liposyn III is also indicated as a source of essential fatty acids to prevent or reverse biochemical changes in fatty acid composition of plasma lipids (elevated triene/tetraene ratio) and the clinical manifestations of EFAD.

DOSAGE
Adult Patients
Liposyn III can provide up to 60% of daily calories at a dose not to exceed 3 g/kg of body weight per day.The other 40% should be provided by carbohydrate and amino acids.
For the prevention of essential fatty acid deficiency, the recommended daily requirement isapproximately 4% of the caloric intake as linoleate. In most adult patients, this can be supplied as 500 mL of Liposyn III 10% or 250 mL of Liposyn III 20% administered three times weekly.
The initial infusion rate for the first 15 minutes should be 1.0 mL/minute for Liposyn III 10% and0.5 mL/minute for Liposyn III 20%. If no adverse effects are observed during this initial infusion, the rate can be increased to allow no more than 500 mL of Liposyn III 10% or 250 mL of Liposyn III 20% to be given over a period of four to six hours.
Pediatric Patients
Liposyn III can provide up to 60% of daily calories at a dose not to exceed 4 g/kg of body weight per day. The other 40% should be provided by carbohydrate and amino acids.
For the prevention of essential fatty acid deficiency, the recommended daily requirement isapproximately 4% of the caloric intake as linoleate. The daily dosage of Liposyn III ranges from 7.5 mL to 15 mL per kilogram for the 10% emulsion and 3.8 mL to 7.5 mL per kilogram for the 20% emulsion, depending upon the size and maturity of the patient.
The infusion should be started at a rate of 0.1 mL/minute for the first 15 minutes. If no adverse effects are observed during this initial infusion, the rate can be increased to allow no more than 100 mL of Liposyn III 10% or 50 mL of Liposyn III 20% per hour.

ADVERSE REACTIONS
Sepsis due to contamination of administration equipment and thrombophlebitis due to vein irritation from concurrently administered hypertonic solutions have been encountered. These are attributable to I.V. therapy in general or to the type of infusion administered.
Adverse reactions directly related to fat emulsions are of two types: (1) immediate (acute) and (2) long term (chronic). In studies of lipid products in general, the following immediate reactions have beennoted: Allergic reactions, hyperlipemia, dyspnea, cyanosis, flushing, dizziness, headache, sleepiness,nausea, vomiting, hyperthermia, sweating, chest and back pain, thrombocytopenia (rarely in neonates),hypercoagulability and transient increases in liver enzymes.
The following reactions have been noted with long-term therapy with lipid infusions in general:
Hepatomegaly, jaundice due to central lobular cholestasis, splenomegaly, thrombocytopenia, leucopenia,transient increases in liver function tests, overloading syndrome and the deposition of brown pigment (“fat pigment”) in the reticuloendothelial tissue of the liver. The significance of this last occurrence and its cause are unknown.

LIPOSYN III(静脉注射脂肪乳剂)

【原产地英文商品名】:LIPOSYN III 20% IV FAT EMUL 12 X 250ML
【原产地英文药品名】:soybean oil + egg phosphatides + glycerin
【中文参考商品译名】:LIPOSYN III 20% IV脂肪乳250毫升/瓶 12瓶/箱
【中文参考药品译名】:豆油+蛋磷脂+甘油
【生产厂家中文参考译名】:Hospira
【生产厂家英文名】:Hospira

责任编辑:admin


相关文章
LIPOSYN III(静脉注射脂肪乳剂)
LIPOSYN III (脂肪乳静脉注射剂)
 

最新文章

更多

· 无水酒精注射液(DEHYDR...
· DEHYDRATED ALCOHOL(无...
· 除铁能注射剂DESFERAL(D...
· ALBUMINAR IV SOLUTION(...
· Dantrium Intravenous I...
· Bunavail(盐酸丁丙诺啡...
· Dyloject(diclofenac so...
· THAM SOLUTION(trometha...
· THAM Injection SET(Tr...
· 首个基因新药Glybera注射...

推荐文章

更多

· 无水酒精注射液(DEHYDR...
· DEHYDRATED ALCOHOL(无...
· 除铁能注射剂DESFERAL(D...
· ALBUMINAR IV SOLUTION(...
· Dantrium Intravenous I...
· Bunavail(盐酸丁丙诺啡...
· Dyloject(diclofenac so...
· THAM SOLUTION(trometha...
· THAM Injection SET(Tr...
· 首个基因新药Glybera注射...

热点文章

更多

· 除铁能注射剂DESFERAL(D...
· DEHYDRATED ALCOHOL(无...
· 无水酒精注射液(DEHYDR...